Evidence map›Paper›PMID 39631366›Full record

ArticleBJU international2025

Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?

Mustafa Soytas, Alice Dragomir, Ghady Bou-Nehme Sawaya, Charles Hesswani, Maude Tanguay, Antonio Finelli, Lori Wood, Ricardo Rendon, Rahul Bansal, Aly-Khan Lalani and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Mustafa SoytasDivision of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada.
Alice DragomirDivision of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada.
Ghady Bou-Nehme SawayaDepartment of Surgery, Faculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada.
Charles HesswaniDivision of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada.
Maude TanguayDivision of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada.
Antonio FinelliPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Lori WoodQueen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada.
Ricardo RendonDivision of Urology, Dalhousie University, Halifax, Nova Scotia, Canada.
Rahul BansalDivision of Urology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.ORCID https://orcid.org/0000-0002-4449-5346
Aly-Khan LalaniDivision of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
Daniel Y C HengDivision of Oncology, University of Calgary, Calgary, Alberta, Canada.
Bimal BhindiDivision of Urology, University of Calgary, Calgary, Alberta, Canada.
Naveen S BasappaDivision of Medical Oncology, Alberta Health Services, Edmonton, Alberta, Canada.
Lucas DeanDivision of Urology, Alberta Health Services, Edmonton, Alberta, Canada.
Alan SoDepartment of Urologic Sciences, University of British Colombia, Vancouver, British Columbia, Canada.
Jasmir G NayakSection of Urology, University of Manitoba, Winnipeg, Manitoba, Canada.
Georg BjarnasonDivision of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Rodney BreauDivision of Urology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID https://orcid.org/0000-0003-2344-9022
Luke LavalleeDivision of Urology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID https://orcid.org/0000-0001-9286-5965
Jean-Baptiste LattoufDivision of Urology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
Frederic PouliotDivision of Urology, Université Laval, Montréal, Quebec, Canada.
Michael BonertDivision of Anatomical Pathology, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada.
Simon TanguayDivision of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada.ORCID https://orcid.org/0000-0001-6947-304X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate and compare the outcomes of patients with localised renal cell carcinoma (RCC) with and without sarcomatoid features and the impact of this on cancer recurrence and survival. MATERIAL AND

methodsThe Canadian Kidney Cancer information system database was used to identify patients diagnosed with localised RCC between January 2011 and December 2022. Patients with pT1-T3, n Nx-N0N1, M0 stage and documented sarcomatoid status were included. Patients with sarcomatoid RCC were categorised according to the sarcomatoid component percentage (%Sarc). Inverse probability of treatment weighting scores were used to balance the groups. Cox proportional hazards models were used to assess the impact of sarcomatoid status and %Sarc on recurrence-free and overall survival.

resultsA total of 6660 patients (201 with and 6459 without sarcomatoid features) with non-metastatic RCC were included. %Sarc data were available in 155 patients, and the median value was 10%. The weighted analysis revealed that the presence of sarcomatoid features was associated with an increased risk of developing metastasis and increased risk of mortality compared to absence of sarcomatoid features. A %Sarc value >10 was associated with an increased risk of developing metastasis and of mortality compared to a %Sarc value ≤10.

conclusionsPatients with a %Sarc >10 have an increased risk of recurrence and mortality. These patients may benefit from a more stringent follow-up and %Sarc could represent an important criterion in the risk assessment for adjuvant therapy.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNephrectomyRetrospective Studiesinverse probability of treatment weightingkidney cancerkidney neoplasmsnephrectomysarcomatoid

Identifiers

PMID39631366
PMCPMC11975170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.